These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36463183)

  • 1. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
    Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
    Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
    Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
    Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
    [No Abstract]   [Full Text] [Related]  

  • 6. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
    Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
    Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
    Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
    Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs.
    Tookes HE; Bartholomew TS; Suarez E; Ekowo E; Ginoza M; Forrest DW; Serota DP; Rodriguez A; Kolber MA; Feaster DJ; Mooss A; Boyd D; Sternberg C; Metsch LR
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109124. PubMed ID: 34781096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
    Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
    J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma.
    Scaramutti C; Hervera B; Rivera Y; Chueng TA; Forrest DW; Suarez E; Serota DP; Alkamli H; Ciraldo K; Bartholomew TS; Tookes HE
    Harm Reduct J; 2024 Feb; 21(1):50. PubMed ID: 38396017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia.
    Schneider KE; White RH; Musci RJ; O'Rourke A; Kilkenny ME; Sherman SG; Allen ST
    J Stud Alcohol Drugs; 2020 Nov; 81(6):740-749. PubMed ID: 33308403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study.
    Shelby T; Zhou X; Barber D; Altice F
    J Med Internet Res; 2021 Jul; 23(7):e25428. PubMed ID: 34259640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Qualitative Analysis of Barriers to Accessing HIV Prevention Services During an HIV Outbreak among Persons who Inject Drugs in West Virginia.
    Hershow RB; Worthington N; Adams M; McDonald R; Wilson S; McBee S; Balleydier S; Curran KG
    AIDS Behav; 2024 Feb; 28(2):669-681. PubMed ID: 38165598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.